142
Participants
Start Date
April 3, 2024
Primary Completion Date
September 30, 2027
Study Completion Date
December 31, 2032
[Ac-225]-PSMA-62 (mCRPC)
"Phase Ia: Administered intravenously per dose escalation scheme. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 6-week cycle for up to 4 cycles.~Phase Ib: Administered intravenously at MTD or one dose level below MTD. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 6-week or 4-week cycle, for a total of 4 cycles."
[Ac-225]-PSMA-62 (OmHSPC)
"Phase Ia: Administered intravenously per dose escalation scheme. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 8-week cycle for up to 2 cycles.~Phase Ib: Administered intravenously at MTD or one dose level below MTD. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 8-week cycle, for a total of 2 cycles."
NOT_YET_RECRUITING
Juravinski, Hamilton
NOT_YET_RECRUITING
Jewish General Hospital, Montreal
RECRUITING
McGill University, Montreal
RECRUITING
Centre Hospitalier Universite de QUEBEC, Québec
NOT_YET_RECRUITING
Hopital De Chicoutimi, Saguenay
RECRUITING
Princess Margaret Cancer Centre, Toronto
RECRUITING
BC Cancer Vancouver, Vancouver
Eli Lilly and Company
INDUSTRY